China · Delayed Price · Currency is CNY Hybio Pharmaceutical Company Description
Hybio Pharmaceutical Co., Ltd. engages in the development, manufacture, and commercialization of therapeutic peptides API and peptide-based drugs in China and internationally.
It offers liraglutide, semaglutide, and exenatide for diabetes; terlipressin, desmopressin, and linaclotide for digestive tract and metabolic system; ganirelix, cetrorelix, and atosiban for obstetrics and gynecology; customized peptides; working standards for the peptide APIs and related impurities; peptide CRO; and CDMO services, which include peptide API synthesis and purification process development, finish dosage form development, reference standard preparation and qualification, impurity and product quality study and analysis, GMP system meeting EU and FDA standard, international and Chinese regulatory, and dossier support.
The company was founded in 1998 and is based in Wuhan, China.
| Country | China |
| Founded | 1998 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 1,035 |
| CEO | Yu Pinxiang |
Contact Details
Address: No. 9, Linkong West Street Wuhan China | |
| Phone | 86 75 5265 88037 |
| Website | hybio.com.cn |
Stock Details
| Ticker Symbol | 300199 |
| Exchange | Shenzhen Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | CNY |
| ISIN Number | CNE1000011T7 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Yu Pinxiang | Executive President and Director |
| Honghong Tu | Vice President, Chief Financial Officer and Accounting Supervisor |
| Di Yang | Vice President, Secretary and Director |
| Zhaohui Zeng | Vice President |
| Min Zhang | Vice President |
| Heng Quan | Vice President of Human Resource and Administration Department |
| Yu Liu | Vice President of Marketing |